{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:47:11Z","timestamp":1782560831609,"version":"3.54.5"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.bonr.2026.101916","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T16:57:03Z","timestamp":1775667423000},"page":"101916","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparison of KN012, a denosumab biosimilar, versus reference denosumab in Chinese postmenopausal women with osteoporosis: efficacy, safety, and population pharmacokinetics in a 12-month phase III study"],"prefix":"10.1016","volume":"29","author":[{"given":"Xiufen","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bonr.2026.101916_bb0005","series-title":"[Eb\/Ol]. (2020-07-07)","author":"A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis","year":"2022"},{"key":"10.1016\/j.bonr.2026.101916_bb0010","series-title":"Prolia\u00ae: summary of product characteristics","author":"Amgen Europe BV","year":"2020"},{"key":"10.1016\/j.bonr.2026.101916_bb0015","series-title":"Prolia\u00ae: prescribing information","author":"Amgen Inc.","year":"2024"},{"key":"10.1016\/j.bonr.2026.101916_bb0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101916_bb0025","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1359\/jbmr.0809010","article-title":"Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial","volume":"24","author":"Brown","year":"2009","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bonr.2026.101916_bb0030","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000496834","article-title":"What does the pipeline promise about upcoming biosimilar antibodies in oncology?","volume":"14","author":"Busse","year":"2019","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.bonr.2026.101916_bb0035","series-title":"Guiding Principles for Clinical Trial Design of Denosumab Injection Biosimilars (Osteoporosis Indication) (Draft for Comments).June","author":"Center for Drug Evaluation, National Medical Products Administration","year":"2020"},{"key":"10.1016\/j.bonr.2026.101916_bb0040","series-title":"Guidelines for the Study of Human Bioavailability and Bioequivalence of Chemical Drug Preparations","author":"CFDA","year":"2018"},{"issue":"2","key":"10.1016\/j.bonr.2026.101916_bb0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.afos.2023.06.001","article-title":"Summary of the Thai Osteoporosis Foundation (TOPF) clinical practice guideline on the diagnosis and management of osteoporosis 2021","volume":"9","author":"Charatcharoenwitthaya","year":"2023","journal-title":"Osteoporos. Sarcopenia"},{"key":"10.1016\/j.bonr.2026.101916_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2024.117371","article-title":"SB16 versus reference denosumab in postmenopausal women with osteoporosis: 18-month outcomes of a phase III randomized clinical trial","volume":"192","author":"Chung","year":"2025","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.bonr.2026.101916_bb0055","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.bonr.2026.101916_bb0060","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bonr.2026.101916_bb0065","series-title":"https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/ethical-use-animals-medicine-testing\/regulatory-acceptance-new-approach-methodologies-nams-reduce-animal-use-testing#main-content","author":"EMA\u2014NAMs Regulatory Acceptance of New Approach Methodologies (NAMs) to Reduce Animal Use Testing","year":"2025"},{"key":"10.1016\/j.bonr.2026.101916_bb0070","series-title":"Prolia (denosumab): EPAR \u2013 public assessment report","author":"European Medicines Agency","year":"2010"},{"key":"10.1016\/j.bonr.2026.101916_bb0075","series-title":"Guidance for industry bioavailability and bioequivalence studies for orally administered drug products-generalconsiderations","author":"FDA","year":"2003"},{"issue":"38","key":"10.1016\/j.bonr.2026.101916_bb0080","first-page":"117","article-title":"Denosumab biosimilar (LY06006) in Chinese postmenopausal osteoporotic women: a randomized, double-blind, placebo-controlled multicenter phase III study","volume":"29","author":"Gu","year":"2022","journal-title":"J. Orthop. Translat."},{"issue":"5","key":"10.1016\/j.bonr.2026.101916_bb0085","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3999\/jscpt.45.187","article-title":"The use of population pharmacokinetic and pharmacodynamic modeling and simulation in anti-osteoporotic drug development: a perspective","volume":"45","author":"Hasegawa","year":"2014","journal-title":"Rinsho yakuri\/Japanese Journal of Clinical Pharmacology and Therapeutics"},{"issue":"11","key":"10.1016\/j.bonr.2026.101916_bb0090","first-page":"1370","article-title":"Prevalence and influencing factors of postmenopausal osteoporosis in women: a meta-analysis","volume":"27","author":"He","year":"2024","journal-title":"Chin. Gen. Pract."},{"issue":"3","key":"10.1016\/j.bonr.2026.101916_bb0095","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1093\/jbmr\/zjae016","article-title":"Equivalence trial of proposed denosumab biosimilar GP2411 and reference denosumab in postmenopausal osteoporosis: the ROSALIA study","volume":"39","author":"Jeka","year":"2024","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bonr.2026.101916_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"issue":"9","key":"10.1016\/j.bonr.2026.101916_bb0105","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/bph.15024","article-title":"Overview of treatment approaches to osteoporosis","volume":"178","author":"Langdahl","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.bonr.2026.101916_bb0110","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2165\/11203300-000000000-00000","article-title":"Denosumab: a review of its use in the treatment of postmenopausal osteoporosis","volume":"28","author":"Moen","year":"2011","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.bonr.2026.101916_bb0115","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.59556\/japi.73.0772","article-title":"A prospective, Active-controlled, Randomized, Double-blind, Multicenter, Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab vs Reference Denosumab in the Treatment of Postmenopausal Osteoporosis","volume":"73","author":"Paul","year":"2025","journal-title":"J. Assoc. Physicians India"},{"issue":"11","key":"10.1016\/j.bonr.2026.101916_bb0120","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s00198-024-07161-x","article-title":"Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis","volume":"35","author":"Reginster","year":"2024","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bonr.2026.101916_bb0125","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/8738959","article-title":"Effect of denosumab on bone mineral density and markers of bone turnover among postmenopausalwomen with osteoporosis","volume":"2016","author":"S\u00e1nchez","year":"2016","journal-title":"J. Osteoporos."},{"issue":"9","key":"10.1016\/j.bonr.2026.101916_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17091146","article-title":"Population PK modeling of denosumab biosimilar MB09 and reference denosumab to establish PK similarity","volume":"17","author":"S\u00e1nchez-Vidaurre","year":"2025","journal-title":"Pharmaceutics"},{"issue":"Suppl. 4","key":"10.1016\/j.bonr.2026.101916_bb0135","doi-asserted-by":"crossref","first-page":"iv30","DOI":"10.1093\/rheumatology\/kex277","article-title":"Biosimilars in rheumatology: a review of the evidence and their place in the treatment algorithm","volume":"56","author":"Schulze-Koops","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.bonr.2026.101916_bb0140","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ecl.2024.08.008","article-title":"postmenopaual Osteoporosis: A Review of Latest Guidelines","volume":"53","author":"Subarajan","year":"2024","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"10.1016\/j.bonr.2026.101916_bb0145","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2165\/11594240-000000000-00000","article-title":"Population pharmacokinetic meta-analysis of denosumab in healthy subjects and postmenopausal women with osteopenia or osteoporosis","volume":"50","author":"Sutjandra","year":"2011","journal-title":"Clin. Pharmacokinet."},{"issue":"7","key":"10.1016\/j.bonr.2026.101916_bb0155","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.12669\/pjms.40.7.9072","article-title":"Bridging the Gap: A narrative review of osteoporosis disability, adipokines, and the role of AI in postmenopausal women","volume":"40","author":"Tariq","year":"2024","journal-title":"Pak J Med Sci."},{"key":"10.1016\/j.bonr.2026.101916_bb0160","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.eprac.2021.02.001","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 update","volume":"4","author":"Watts","year":"2021","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.bonr.2026.101916_bb0165","series-title":"Guidelines for preclinical evaluation and clinical trials in osteoporosis","author":"World Health Organization","year":"1998"},{"issue":"2","key":"10.1016\/j.bonr.2026.101916_bb0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/13543784.2021.1863371","article-title":"Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects","volume":"30","author":"Zhang","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.bonr.2026.101916_bb0170","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41401-022-00954-y","article-title":"A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk","volume":"44","author":"Zhang","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.bonr.2026.101916_bb0180","first-page":"57","article-title":"Fracture risk prediction tools in elderly patients with osteoporosis: a scoping review","volume":"30","author":"Zhang","year":"2023","journal-title":"J. Nurs."}],"container-title":["Bone Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352187226000203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T11:29:57Z","timestamp":1782559797000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352187226000203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":35,"alternative-id":["S2352187226000203"],"URL":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101916","relation":{},"ISSN":["2352-1872"],"issn-type":[{"value":"2352-1872","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of KN012, a denosumab biosimilar, versus reference denosumab in Chinese postmenopausal women with osteoporosis: efficacy, safety, and population pharmacokinetics in a 12-month phase III study","name":"articletitle","label":"Article Title"},{"value":"Bone Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bonr.2026.101916","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101916"}}